Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2025-11-21
Product name:
MENVEO
Description:
SINGLE-USE VIAL
DIN:
02563029
Product Monograph/Veterinary Labelling:
Date:
2025-11-21
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
GLAXOSMITHKLINE INC
800
100 Milverton Drive
Mississauga
Ontario
Canada
L5R 4H1
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intramuscular
Number of active ingredient(s):
4
Schedule(s):
SCHEDULE D
American Hospital Formulary Service (AHFS): See footnote 3
80:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
J07AH08 MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED
Active ingredient group (AIG) number:See footnote5
0467793001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| MENINGOCOCCAL GROUP A OLIGOSACCHARIDE | 10 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP C OLIGOSACCHARIDE | 5 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE | 5 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE | 5 MCG / 0.5 ML |